Navigation Links
St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership
Date:9/19/2008

- Focusing on Development of Treatments For Women with Endometriosis -

PHOENIX and BRITISH COLUMBIA, Canada, Sept. 19 /PRNewswire-FirstCall/ -- St. Joseph's Hospital and Medical Center, part of Catholic Healthcare West, one of the largest healthcare systems in the West with 42 hospitals in Arizona, California and Nevada and InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces a collaborative partnership focusing on the development of treatments for women with endometriosis.

"I am pleased to announce this new partnership between St. Joseph's Hospital and InNexus to explore, develop and commercialize new therapeutic solutions for women," said Jeff Morhet, Chairman and CEO of InNexus Biotechnology, "We've already identified our first project, aimed at providing new treatments to attack the problem of endometriosis, a painful condition that can lead to other conditions, such as infertility."

"We're excited to join InNexus in pursuing new treatments to help women with endometriosis," says Linda Hunt, President of St. Joseph's. "We hope this is the first of many collaborations that will ultimately help patients in need."

Scientific activities of the partnership will be conducted in facilities of both St. Joseph's Hospital and Medical Center and InNexus' GLP (Good Lab Practice) certified drug development laboratories with funding provided by research grants, the partners and strategic collaborators. Additional details were not disclosed.

About Endometriosis

According to the National Institutes of Health, endometriosis occurs when tissues that usually grow inside the uterus instead grow on the outside. These tissues often grow on the surfaces of organs in the pelvis or abdomen, where they are not supposed to grow.

Endometriosis is one of the most common gynecological diseases, affecting more than 5.5 million women in North America. An estimated 2 to 10 percent of women of reproductive age have endometriosis. Additional information can be found at http://www.nichd.nih.gov/health/topics/endometriosis.cfm.

About St. Joseph's Hospital and Medical Center

Located in the heart of Phoenix, Arizona, St. Joseph's Hospital and Medical Center is a 743-bed, not-for-profit hospital that is recognized for outstanding patient care, medical education and research. The hospital is part of Catholic Healthcare West (CHW), one of the largest healthcare systems in the West with 42 hospitals in Arizona, California and Nevada. You can find out more about St. Joseph's Hospital and Medical Center at http://www.stjosephs-phx.org.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.; St. Joseph's Hospital andMedical Center
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
2. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
5. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
6. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
7. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
8. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
9. Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
10. St. Lukes Episcopal Hospital to Add CyberKnife System to Treatment Offerings
11. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):